The significant hydrogen bonding and hydrophobic contacts in ESR1’s ligand-binding domain indicate that medicarpin may operate as a partial antagonist, diminishing estrogen-mediated transcriptional activities linked to tumor growth. This evidence concerns the gene ESR1 and neoplasm.